BioSpace News Archive

The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China’s aging population ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced it has entered into an agreement to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited.

CytRx Corporation announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022.

Edesa Biotech, Inc. announced that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

The global Clinical Laboratory Service market size is estimated to be worth around US$ 288.10 billion by 2030 and it is anticipated to grow at a registered CAGR of 4.10% from 2021 to 2030.

According to Vision Research Reports, the global Cancer Biopsy market size is estimated to hit around US$ 40.65 billion by 2030 from valued at US$ 21.8 billion in 2020, growing at a CAGR of 10.35% from 2021 to 2030.

Centene Corporation will host its next Investor Meeting in a virtual format on Friday, June 17th, 2022.

BioOhio, the state’s bioscience trade organization, today announced the creation of a Gene and Cell Therapy Industry Council to amplify industry support for the growing momentum of this category across the state of Ohio.

The global Clinical Trial Kits market size is expected to be worth around US$ 5.1 billion by 2030, according to a new report by Vision Research Reports.

POINT Biopharma Global Inc. announced that the Company’s Chief Executive Officer, Dr. Joe McCann, will participate in the following upcoming investor conferences.

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs. standard of care (SOC; fulvestrant or aromatase inhibitor, AI) for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.